Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17620057 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Wong S, Weber JD (2007) Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J 407, 451-60 17620057
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

K382-a - p53 (human) ▲
Orthologous residues
p53 (human): K382‑a, p53 (mouse): K376‑a, p53 iso2 (mouse): ‑, p53 (rat): K380‑a, p53 (rabbit): K380‑a, p53 (monkey): K382‑a
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
ACETYLTRANSFERASE p300 (human)
DEACETYLASE SIRT1 (human)

K873-a - Rb (human) ▲
Orthologous residues
Rb (human): K873‑a, Rb (mouse): K866‑a, Rb (rat): K865‑a
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  BJT [SIRT1 (human), transfection]
 Cellular systems studied:  cell lines
 Enzymes shown to modify site in vitro: 
Type Enzyme
ACETYLTRANSFERASE p300 (human)
DEACETYLASE SIRT1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DEACETYLASE SIRT1 (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nicotinamide increase
siRNA nicotinamide augment treatment-induced increase SirT1 siRNA
siRNA increase SirT1 siRNA
etoposide increase
nicotinamide etoposide augment treatment-induced increase

K874-a - Rb (human) ▲
Orthologous residues
Rb (human): K874‑a, Rb (mouse): K867‑a, Rb (rat): K866‑a
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, modification-specific antibody, western blotting
 Relevant cell lines - cell types - tissues:  BJT [SIRT1 (human), transfection]
 Cellular systems studied:  cell lines
 Enzymes shown to modify site in vitro: 
Type Enzyme
ACETYLTRANSFERASE p300 (human)
DEACETYLASE SIRT1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DEACETYLASE SIRT1 (human) siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nicotinamide increase
siRNA nicotinamide augment treatment-induced increase SirT1 siRNA
siRNA increase SirT1 siRNA
etoposide increase
nicotinamide etoposide augment treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.